Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 6:48 PM
Ignite Modification Date:
2025-12-24 @ 6:48 PM
NCT ID:
NCT03245957
Brief Summary:
The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.
Detailed Description:
MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.
Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.
The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.
Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.
Study:
NCT03245957
Study Brief:
Protocol Section:
NCT03245957